Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

AI Briefing

• – Arbutus Pharmaceuticals' imdusiran receives FDA Fast Track designation for treatment of chronic hepatitis B.
• – Fast Track designation enables expedited development and review process.
• – Imdusiran shows potential to address unmet need for patients with advanced fibrosis in chronic hepatitis B.